NCT06401447进行中（未招募）不适用
Medium Dose of Three Drugs (TPF) Concurrent Chemoradiotherapy Combined With PD-1 Checkpoint Inhibitor for Locally Advanced Esophageal Squamous Cell Carcinoma --Prospective, Single Center, Single Arm, Phase II Clinical Study (FUTURE-2)
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Progression Free Survival
研究概览
简要总结
The goal of this clinical trial is to learn if immune microenvironment modification could improve the effect of chemoradiotherapy for patients with local advanced esophageal squamous cell carcinoma. The main questions it aims to answer are:
- Does immune microenvironment could be modified by medium dose of three drugs (paclitaxel, cisplatin, 5-FU), PD1 checkpoint inhibitor, probiotics, and thymosin α1？
- Does induction and consolidation of PD1 checkpoint inhibitor improve the effect of chemoradiotherapy for patients with esophageal cancer?
This is a single arm study. Participants will:
- Take one cycle of induction chemotherapy (paclitaxel, cisplatin, 5-FU) and immunotherapy (Sintilimab), two cycle of concurrent chemoradiotherapy, one cycle of consolidation chemo-immunotherapy, and then 1 year of immunotherapy.
- Take probiotics (Clostridium Butyricum) for 1 year and thymosin alpha-1 daily during radiotherapy.
详细描述
Concurrent chemoradiotherapy is the standard treatment for patients with inoperable local advanced esophageal squamous cell carcinoma. However, over half of patients will relapse. How to improve effects? We focus on tumor microenvironment transformation by three drug chemotherapy, PD1 inhibitor, probiotics, and thymosin α1，and intent to improve radiosensitivity and reduce recurrence.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign written informed consent before implementing any trial related procedures;
- •Age range from 18 to 80 years old;
- •Stage II-III and stage IV esophageal squamous cell carcinoma with only extraregional lymph node metastasis determined by histopathology;
- •Inability to undergo surgical resection or patient refusal to undergo surgery;
- •ECOG PS 0-1;
- •Expected survival time>3 months;
- •Sufficient organ function is required for the subject to meet laboratory indicators
排除标准
- •After esophageal or tracheal stent implantation surgery;
- •Due to the obvious invasion of tumors into adjacent organs (arteries or trachea) of the esophageal lesion, there is a higher risk of Patients at risk of bleeding or perforation, or those who have formed fistulas;
- •Diagnosed as malignant diseases other than esophageal cancer within 3 years prior to initial administration (excluding those that have undergone curative treatment)
- •Currently participating in intervention clinical research treatment, or having received other treatments within 4 weeks prior to initial administration Researching drugs or using research instruments for treatment;
- •Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or targeting another stimulus or synergistic inhibition of T cell receptors (such as CTLA-4, OX-40, CD137) Medications;
研究组 & 干预措施
Treatment Arm
Experimental
- Take one cycle of induction chemo-immunotherapy, two cycle of concurrent chemoradiotherapy 3 weeks later, one cycle of consolidation chemo-immunotherapy 1 month after radiotherapy, and then 1 year of immunotherapy.
- Radiotherapy: intensity modulated radiotherapy or volume modulated therapy. Modified involving field irradiation. PTV-C of 50.4Gy/28F, and PTV-G of 61.6Gy/28F with simultaneous integrated boost if no deep ulcers.
- Chemotherapy: paclitaxel 60mg/m2, ivgtt; cisplatin 30mg/m2, ivgtt; 5-FU 500mg/m2, ivgtt and 500mg/m2, civ 24h; calcium folinate 200mg; q3w.
- Immunotherapy: Sintilimab, 200mg, q3w.
- Probiotics: Clostridium Butyricum (MIYAIRI 588), 20mg, tid, for 1 year.
- Thymosin alpha-1: 1.6mg, qd, d1-5 during radiotherapy.
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Progression Free Survival
时间窗: 1 year
From firt treatment to any disease progression or death
次要结局
- clinical complete response(1 month after radiotherapy)
- Overall survival(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Nivolumab and Eribulin in HER2 Negative Metastatic Breast CancerMetastatic Breast CancerNCT04061863Seoul National University Hospital90
招募中
3 期
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8NCT06096844National Cancer Institute (NCI)304
进行中（未招募）
2 期
Cisplatin+Pembrolizumab+RT in Vulvar CancerVulvar Squamous Cell CarcinomaVulvar CancerNCT04430699Massachusetts General Hospital24
已完成
不适用
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System LymphomaLymphomaNCT00594815Memorial Sloan Kettering Cancer Center52
已完成
1 期
Chemoimmunotherapy and Radiation in Pancreatic CancerLocally Advanced Malignant NeoplasmNCT01903083Providence Health & Services10